CR9847A - Derivados de piridina y su uso en el tratamiento de transtornos psicoticos - Google Patents

Derivados de piridina y su uso en el tratamiento de transtornos psicoticos

Info

Publication number
CR9847A
CR9847A CR9847A CR9847A CR9847A CR 9847 A CR9847 A CR 9847A CR 9847 A CR9847 A CR 9847A CR 9847 A CR9847 A CR 9847A CR 9847 A CR9847 A CR 9847A
Authority
CR
Costa Rica
Prior art keywords
piridine
derivatives
treatment
psychotic disorders
ch2oh
Prior art date
Application number
CR9847A
Other languages
English (en)
Spanish (es)
Inventor
Alvaro Giuseppe
Andreotti Daniele
Bevedere Sandro
Fabio Romano
Falchi Alessandro
Giovannini Riccardo
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9847(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0518472A external-priority patent/GB0518472D0/en
Priority claimed from GB0611153A external-priority patent/GB0611153D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR9847A publication Critical patent/CR9847A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR9847A 2005-09-09 2008-03-28 Derivados de piridina y su uso en el tratamiento de transtornos psicoticos CR9847A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0518472A GB0518472D0 (en) 2005-09-09 2005-09-09 Novel compounds
GB0611153A GB0611153D0 (en) 2006-06-06 2006-06-06 Novel compounds

Publications (1)

Publication Number Publication Date
CR9847A true CR9847A (es) 2008-07-29

Family

ID=37546936

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9847A CR9847A (es) 2005-09-09 2008-03-28 Derivados de piridina y su uso en el tratamiento de transtornos psicoticos

Country Status (28)

Country Link
US (3) US7683056B2 (2)
EP (2) EP1928886B1 (2)
JP (1) JP5121716B2 (2)
KR (1) KR101292348B1 (2)
CN (1) CN101305011B (2)
AR (1) AR058805A1 (2)
AT (1) ATE505472T1 (2)
AU (1) AU2006289281B2 (2)
BR (1) BRPI0615787B8 (2)
CA (1) CA2621564C (2)
CR (1) CR9847A (2)
CY (1) CY1111907T1 (2)
DE (1) DE602006021323D1 (2)
DK (1) DK1928886T3 (2)
EA (1) EA013909B1 (2)
HR (1) HRP20110457T1 (2)
IL (1) IL189578A (2)
JO (1) JO2722B1 (2)
MA (1) MA29780B1 (2)
MY (1) MY145713A (2)
NO (1) NO340921B1 (2)
NZ (1) NZ565983A (2)
PE (1) PE20070614A1 (2)
PL (1) PL1928886T3 (2)
PT (1) PT1928886E (2)
SI (1) SI1928886T1 (2)
TW (1) TWI378101B (2)
WO (1) WO2007028654A1 (2)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
EP2639224B1 (en) 2007-12-07 2016-08-24 Vertex Pharmaceuticals Incorporated Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
EP2098526B1 (en) * 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009119528A1 (ja) * 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
PL2470545T3 (pl) * 2009-08-27 2014-03-31 Nerre Therapeutics Ltd Bezwodne postaci pochodnej pirydyny
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
ES2529233T3 (es) 2010-07-09 2015-02-18 Convergence Pharmaceuticals Limited Compuestos tetrazol como bloqueadores de canales de calcio
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
CN102617503B (zh) * 2011-03-03 2014-05-07 上海常丰生物医药科技有限公司 (s)-3-吗啉基羧酸的合成方法
WO2013049164A1 (en) * 2011-09-29 2013-04-04 Abbvie Inc. SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
UY34349A (es) 2011-09-29 2013-04-05 Abb Vie Inc OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP2016503007A (ja) 2012-12-12 2016-02-01 アッヴィ・インコーポレイテッド 疼痛治療におけるカルシウムチャネル遮断薬として有用なジアゼピン誘導体
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016021562A1 (ja) * 2014-08-06 2016-02-11 キッセイ薬品工業株式会社 シアノチオフェン誘導体
PT3221692T (pt) 2014-11-18 2021-09-10 Vertex Pharma Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
SMT201900719T1 (it) * 2015-05-18 2020-01-14 Nerre Therapeutics Ltd Antagonista del recettore nk-1/nk-3 per il trattamento delle vampate di calore
US11192856B2 (en) 2017-10-05 2021-12-07 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
AU2019233606B2 (en) 2018-03-14 2024-10-03 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
PE20221167A1 (es) 2019-11-15 2022-07-25 Kandy Therapeutics Ltd Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2-metilfenil)piridin-3-amina, un intermediario clave de nt-814
KR102682775B1 (ko) * 2020-06-26 2024-07-08 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2021261969A1 (ko) * 2020-06-26 2021-12-30 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
KR20240004329A (ko) * 2021-04-05 2024-01-11 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 신경전달에 대한 거울상이성질체 선택적 작용
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025261856A1 (en) 2024-06-18 2025-12-26 Bayer Consumer Care Ag Improved process for producing an elinzanetant precursor
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921855A (en) 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
US5166203A (en) 1990-08-30 1992-11-24 Kanebo, Ltd. Quinolinecarboxylic acid derivatives, antibacterial agent containing the same
SI1004583T1 (en) 1998-11-23 2004-12-31 Pfizer Products Inc. Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
RU2347777C2 (ru) 2003-07-03 2009-02-27 Ф.Хоффманн-Ля Рош Аг Двойные агонисты nk1/nk3 для лечения шизофрении

Also Published As

Publication number Publication date
HRP20110457T1 (hr) 2011-07-31
DE602006021323D1 (de) 2011-05-26
CA2621564A1 (en) 2007-03-15
CA2621564C (en) 2014-06-03
EP1928886B1 (en) 2011-04-13
EP2336136A1 (en) 2011-06-22
EA013909B1 (ru) 2010-08-30
MY145713A (en) 2012-03-30
NZ565983A (en) 2011-04-29
CN101305011A (zh) 2008-11-12
KR20080046232A (ko) 2008-05-26
JO2722B1 (en) 2013-09-15
EA200800784A1 (ru) 2008-06-30
JP5121716B2 (ja) 2013-01-16
TW200804401A (en) 2008-01-16
KR101292348B1 (ko) 2013-09-09
EP1928886A1 (en) 2008-06-11
US20100152175A1 (en) 2010-06-17
US8097618B2 (en) 2012-01-17
BRPI0615787B8 (pt) 2021-05-25
JP2009507801A (ja) 2009-02-26
SI1928886T1 (sl) 2011-08-31
US20110190276A1 (en) 2011-08-04
BRPI0615787B1 (pt) 2020-08-11
IL189578A0 (en) 2008-08-07
NO20081728L (no) 2008-04-07
AU2006289281A1 (en) 2007-03-15
AR058805A1 (es) 2008-02-27
IL189578A (en) 2015-10-29
MA29780B1 (fr) 2008-09-01
US7919491B2 (en) 2011-04-05
DK1928886T3 (da) 2011-07-11
US20080269208A1 (en) 2008-10-30
ATE505472T1 (de) 2011-04-15
PE20070614A1 (es) 2007-08-02
US7683056B2 (en) 2010-03-23
PT1928886E (pt) 2011-07-14
NO340921B1 (no) 2017-07-17
CY1111907T1 (el) 2015-11-04
BRPI0615787A2 (pt) 2009-06-16
WO2007028654A1 (en) 2007-03-15
AU2006289281B2 (en) 2012-05-17
CN101305011B (zh) 2011-03-02
PL1928886T3 (pl) 2011-09-30
TWI378101B (en) 2012-12-01

Similar Documents

Publication Publication Date Title
CR9847A (es) Derivados de piridina y su uso en el tratamiento de transtornos psicoticos
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
UY30334A1 (es) Derivados de triazolopirazina
MY143698A (en) Substituted morpholine and thiomorpholine derivatives.
HRP20050070B1 (hr) 3-2-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primjena kao farmaceutskog pripravka
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
ECSP088549A (es) Nuevos derivados de pirrol fusionado
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
DK1542997T3 (da) Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
DE60315814D1 (de) Drehschwenkmechanismus eines tragbaren fernsprechers
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
ATE446949T1 (de) Neues a-liponsäurederivat und dessen verwendung
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
AU2003269364A1 (en) Use of piperazine derivatives as ccr1 antagonists
ATE457302T1 (de) Aromatische etherderivate als thrombin-hemmer
AR076362A1 (es) Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras.
MXPA05009282A (es) Derivados de anilina sustituidos.
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
CO6150165A2 (es) Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)